Explore original, structured summaries for research and education.
Research profile
HGH Fragment 176-191(HGH Frag)
HGH Fragment 176-191(HGH Frag) is indexed as a hGH C-terminal fragment (176-191) research entry. Its current evidence category is (HGH Frag), and published discussion commonly places it within Weight Loss, Metabolic. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 1,817.1 Da
- Chain length
- 16 amino acids
- Type
- hGH C-terminal fragment (176-191)
- Reported half-life
- 15-20 minutes
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheLiterature map
Research indications
Fat Loss
- Lipolysis Enhancementmost effective
- Lipogenesis Inhibitioneffective
- Body Compositioneffective
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for HGH Fragment 176-191(HGH Frag). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of HGH Fragment 176-191(HGH Frag) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is HGH Fragment 176-191(HGH Frag) approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragmentHeffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM · International Journal of Obesity · 2001
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out miceHeffernan MA, Jiang WJ, Thorburn AW, Ng FM · Endocrinology · 2001
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormoneNg FM, Jiang WJ, Gianello R, Pitt C, Heffernan M · Hormone Research · 2000
- Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolismHeffernan MA, Heffernan MJ, Jiang WJ, Thorburn AW, Ng FM · American Journal of Physiology – Endocrinology and Metabolism · 2000